Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

Novavax said on Thursday discussions with the U.S. health regulator on its COVID-19 shot are ongoing and a pathway to ...

Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the ...

Novavax (NASDAQ:NVAX) pivots back to profitability after delivering a $666.7 million revenue haul in Q1surpassing estimates ...

After more than a month of speculation over how the FDA will rule on Novavax’s application for an updated formulation of its ...

Novavax Inc. closed 74.96% below its 52-week high of $23.86, which the company reached on June 6th.

UnitedHealth sued over allegedly hiding business impact from Brian Thompson's killing UnitedHealth Group (NYSE:UNH) was sued by shareholders on Wednesday for allegedly hiding how business was impacted ...

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top ...

Novavax (NVAX) stock jumps 35% as the company raises its 2025 revenue outlook and its Q1 2025 financials surpasses forecasts ...

QBTS: D-Wave Quantum shares are rallying after the company beat analysts' estimates and reported record quarterly revenue ...

Novavax Inc. closed 73.72% short of its 52-week high of $23.86, which the company achieved on June 6th.

Novavax sees pathway to FDA approval after post-marketing commitments Swings to profit in Q1 Shares rise nearly 19% May 8 (Reuters) - Novavax (NVAX.O), opens new tab on Thursday tried to calm ...